title: KDM2A Gene
KDM2A (Lysine Demethylase 2A), also known as FBXL11 or JHDM1A (Jumonji Domain-Containing Histone Demethylase 1A), is a histone demethylase that specifically removes methyl groups from histone H3 at lysine 36 (H3K36). This enzyme plays critical roles in regulating transcription, DNA repair, cellular differentiation, and has emerged as a significant player in neurodegenerative disease pathogenesis. KDM2A belongs to the JmjC domain-containing family of histone demethylases, which are Fe(II) and 2-oxoglutarate-dependent oxygenases that catalyze the oxidative removal of methyl groups from lysine residues on histone tails. [@tsukada2006, @kooistra2012]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | KDM2A |
| Gene Name | Lysine Demethylase 2A |
| Aliases | FBXL11, JHDM1A, NEDMCL, CXXC8 |
| Chromosomal Location | 11q13.1 |
| NCBI Gene ID | [22992](https://www.ncbi.nlm.nih.gov/gene/22992) |
| OMIM | [605469](https://www.omim.org/entry/605469) |
| UniProt | [Q9Y2K2](https://www.uniprot.org/uniprot/Q9Y2K2) |
| Ensembl | [ENSG00000107140](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107140) |
| Protein Class | Fe(II)/2-oxoglutarate-dependent dioxygenase |
| Expression | Ubiquitous, highest in brain and testis |
</div>
title: KDM2A Gene
KDM2A (Lysine Demethylase 2A), also known as FBXL11 or JHDM1A (Jumonji Domain-Containing Histone Demethylase 1A), is a histone demethylase that specifically removes methyl groups from histone H3 at lysine 36 (H3K36). This enzyme plays critical roles in regulating transcription, DNA repair, cellular differentiation, and has emerged as a significant player in neurodegenerative disease pathogenesis. KDM2A belongs to the JmjC domain-containing family of histone demethylases, which are Fe(II) and 2-oxoglutarate-dependent oxygenases that catalyze the oxidative removal of methyl groups from lysine residues on histone tails. [@tsukada2006, @kooistra2012]
<div class="infobox infobox-gene">
| Property | Value |
|----------|-------|
| Gene Symbol | KDM2A |
| Gene Name | Lysine Demethylase 2A |
| Aliases | FBXL11, JHDM1A, NEDMCL, CXXC8 |
| Chromosomal Location | 11q13.1 |
| NCBI Gene ID | [22992](https://www.ncbi.nlm.nih.gov/gene/22992) |
| OMIM | [605469](https://www.omim.org/entry/605469) |
| UniProt | [Q9Y2K2](https://www.uniprot.org/uniprot/Q9Y2K2) |
| Ensembl | [ENSG00000107140](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000107140) |
| Protein Class | Fe(II)/2-oxoglutarate-dependent dioxygenase |
| Expression | Ubiquitous, highest in brain and testis |
</div>
KDM2A catalyzes the demethylation of histone lysine residues through a hydroxylation-based mechanism requiring:
KDM2A demonstrates the following substrate specificity:
KDM2A contains several functional domains:
KDM2A functions as part of larger protein complexes:
KDM2A plays a complex role in transcription through histone demethylation:
Repressive Function: By removing H3K36me2 (a mark associated with active transcription), KDM2A promotes transcriptional repression. This is particularly important at:
KDM2A is recruited to DNA damage sites and regulates the repair of various types of DNA damage:
Nucleotide Excision Repair (NER): KDM2A demethylates H3K36me2 at DNA damage sites, allowing recruitment of repair factors like XPA and XPG. This facilitates the removal of bulky DNA adducts and helix-distorting lesions.
Base Excision Repair (BER): KDM2A modulates chromatin accessibility at sites of oxidative DNA damage, affecting the recruitment of DNA glycosylases and downstream repair components.
DNA Damage Checkpoint: KDM2A regulates the expression of cell cycle checkpoint genes through histone modifications, ensuring proper cell cycle arrest in response to DNA damage. [@nottke2009]
KDM2A controls cell proliferation through multiple mechanisms:
G1/S Transition: KDM2A represses cyclin-dependent kinase inhibitors and promotes the expression of S-phase entry genes, facilitating the G1 to S transition.
Cell Cycle Exit: During differentiation, KDM2A promotes cell cycle exit by repressifying proliferation genes and allowing the establishment of differentiation-specific chromatin states.
Senescence: KDM2A is upregulated during cellular senescence and contributes to the senescence-associated secretory phenotype (SASP) through epigenetic regulation of inflammatory genes. [@janzer2012]
Emerging evidence highlights critical roles for KDM2A in the nervous system:
Neural Stem Cell Maintenance: KDM2A regulates the balance between neural stem cell self-renewal and differentiation. Loss of KDM2A in neural progenitor cells leads to premature differentiation and depletion of the stem cell pool. [@wang2013]
Neuronal Differentiation: During cortical development, KDM2A is dynamically expressed and controls the timing of neuronal differentiation through epigenetic regulation of Notch signaling pathway genes and other key developmental regulators. [@cho2015]
Synaptic Plasticity: KDM2A is expressed in post-mitotic neurons and may regulate synaptic plasticity-related gene expression, though this remains an area of active investigation.
KDM2A exhibits tissue-specific expression:
KDM2A has emerged as a significant player in Alzheimer's disease pathogenesis through multiple mechanisms:
Amyloid Metabolism: Studies have shown that KDM2A regulates amyloid precursor protein (APP) processing and amyloid-beta (Aβ) production. KDM2A deficiency leads to increased Aβ generation through alterations in γ-secretase component expression and altered chromatin states at APP-processing genes. [@chen2022]
Tau Pathology: KDM2A regulates tau phosphorylation and aggregation through modulation of kinase and phosphatase expression. In AD models, KDM2A dysregulation contributes to hyperphosphorylated tau accumulation and neurofibrillary tangle formation. [@park2020]
Neuroinflammation: KDM2A modulates neuroinflammatory responses in AD by regulating the expression of cytokines and inflammatory mediators. Loss of KDM2A in microglia leads to heightened inflammatory responses and increased neurotoxicity. [@fan2017]
Epigenetic Dysregulation: Global histone methylation changes are observed in AD brain, with altered H3K36me2 patterns correlating with disease progression. This suggests broader epigenetic dysfunction involving KDM2A and related enzymes. [@zhang2016]
KDM2A is implicated in Parkinson's disease through several mechanisms:
α-Synuclein Regulation: KDM2A may regulate the expression of SNCA (the gene encoding α-synuclein) through epigenetic mechanisms. Altered KDM2A activity could contribute to α-synuclein aggregation in PD. [@zhao2018]
Mitochondrial Function: KDM2A regulates genes involved in mitochondrial dynamics and function. In PD models, KDM2A dysregulation contributes to mitochondrial dysfunction, a hallmark of dopaminergic neuron degeneration.
Oxidative Stress: KDM2A responds to oxidative stress by regulating antioxidant gene expression. Impaired KDM2A function may exacerbate oxidative damage in PD pathogenesis.
Neuroinflammation: Similar to AD, KDM2A modulates microglial activation and neuroinflammatory responses in PD models.
Amyotrophic Lateral Sclerosis (ALS): KDM2A expression is altered in ALS models and patient tissue, with implications for motor neuron survival and protein homeostasis.
Huntington's Disease: KDM2A may regulate mutant huntingtin expression and function, though this requires further investigation.
Aging-Related Neurodegeneration: KDM2A is considered a "gerontogene" - its expression and activity change with age, contributing to age-related cognitive decline and increased susceptibility to neurodegenerative diseases. [@khan2019]
Several KDM2A inhibitors have been developed and tested in preclinical models:
Several approaches are being explored:
KDM2A is a Fe(II)/2-oxoglutarate-dependent histone demethylase with substrate specificity for H3K36me2. Through its catalytic activity and protein-protein interactions, KDM2A regulates transcription, DNA repair, cell cycle progression, and neural development. Growing evidence implicates KDM2A dysregulation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders, making it a promising therapeutic target. Understanding the precise mechanisms by which KDM2A contributes to neurodegeneration will be critical for developing effective neuroprotective strategies. [@wang2023]